4006-776-356 出国就医服务电话

免费获得国外相关药品,最快 1 个工作日回馈药物信息

出境医 / 临床实验 / A Multicenter Trial of Radiofrequency Ablation vs. Surgery as Treatment of Papillary Thyroid Microcarcinoma.

A Multicenter Trial of Radiofrequency Ablation vs. Surgery as Treatment of Papillary Thyroid Microcarcinoma.

Study Description
Brief Summary:
The treatment of Papillary Thyroid Microcarcinoma (PTMC) nowadays varies among physicians, surgeons and radiologist. The recently published articles show that the prognosis of PTMC by different means of treatment strategies tends to be good. But multicentered, randomized, parallel and prospective study is rare. RFA is the abbreviation of "Radiofrequency Ablation", which tends to be an alternative strategy except conventional surgery. The investigator aims to confirm whether RFA for treating PTMC braces same effectiveness and prognosis comparing with conventional surgery. Besides, this trial also investigates the safety, economy and psychological quality under different treatments.

Condition or disease Intervention/treatment Phase
Papillary Thyroid Microcarcinoma Procedure: Radiofrequency Ablation Procedure: Conventional Surgery Not Applicable

Detailed Description:

The incidence of thyroid carcinoma, especially the papillary thyroid microcarcinoma (PTMC), has increasingly rapidly, due to the development of technologies of diagnosis, during the past 20 years. PTMC defined by the World Health Organization (WTO) as the largest dimension less than 1 cm. Previous autopsy study demonstrated that the lesions are normal in many people and accompany them latently until they die because of another reasons. The long-term outcome of PTMC is good and, as expected, more than 90% PTMC aren't progress for many years.

Ultrasound-guided Radiofrequency Ablation (RFA) treatment was introduced to clinical practice few years ago. According to the 2015 American Thyroid Association (ATA) guideline, the treatment of radiofrequency and laser ablation are mentioned to be used in recurrent thyroid cancer. But clinical practice shows that the RFA treatment for low risk PTMC braces well effect,low financial budget,high safety and even rare postoperative complication.

Although the cohort study was performed before, the real answer concerning about whether RFA is a rational choice for treating PTMC lacks more powerful evidences. The investigator considers to perform a randomized, controlled and multicenter study as a high-quality evidence and demonstrated the effect of PRF in low risk PTMC treatment.

Study Design
Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 200 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Multicenter, Randomized and Controlled Trial of Radiofrequency Ablation vs. Conventional Surgery as Treatment of Papillary Thyroid Microcarcinoma (PTMC)
Actual Study Start Date : June 1, 2019
Estimated Primary Completion Date : February 1, 2024
Estimated Study Completion Date : February 1, 2024
Arms and Interventions
Arm Intervention/treatment
Experimental: Radiofrequency Ablation
Eligible participants with PTMC will be randomly assigned to this group and undergo radiofrequency ablation(RFA) procedure.
Procedure: Radiofrequency Ablation
Patients were supine with the neck exposure completely during the procedure. Local anesthesia with 1% lidocaine was injected at the subcutaneous puncture site and the thyroid anterior capsule. If the distance between the tumor and critical cervical structures was less than 5 mm, normal saline was injected to form at least 1 cm distance between the tumor and the critical structure to prevent the unwilling thermal injury. RFA was performed using the moving-shot technique and RFA power was 5 W, if a transient hyperechoic zone did not form at the electrode tip within 5-10 seconds. The RFA extent exceeded the tumor edge to prevent marginal residue and recurrence. The ablation was terminated when all portions of the target ablation area had changed to hyperechoic zones.
Other Name: RFA

Active Comparator: Conventional Surgery
Eligible participants with PTMC will be randomly assigned to this group and undergo total/thyroid lobectomy procedure.
Procedure: Conventional Surgery
Patient is performed total thyroidectomy or thyroid lobectomy depending on the intraoperative situation, disease condition and comprehensive judge by surgeon. Patients are routinely disinfected and spread the drapes after general anesthesia. Neck skin, fat and placenta muscle are incised and separated successively. The flap is separated to the upper edge of thyroid cartilage, neck white line is incised and anterior muscle group is separated. Then both sides thyroid lobes are exposed. Cut off the isthmus, ligature the thyroid artery, cut off the upper pole. Ligature and cut off the ipsilateral thyroid vein. Reveal and protect the ipsilateral recurrent laryngeal nerve and the parathyroid gland during the entire process.
Other Name: Total thyroidectomy/Thyroid lobectomy

Outcome Measures
Primary Outcome Measures :
  1. Recurrent-free Survival Rate [ Time Frame: 5 years ]
    record detecting recurrence of PTMC post-surgery or post-FRA


Secondary Outcome Measures :
  1. The Diameter of Lesion [ Time Frame: 5 years ]
    record diameter reduce rate after RFA procedure

  2. The Volume of Lesion [ Time Frame: 5 years ]
    record volume reduce rate after RFA procedure

  3. Postoperative Complications [ Time Frame: up to 12 months ]
    record relevant complications after surgery or RFA

  4. Serum Concentration of Serological Examination of Thyroid Function [ Time Frame: up to 12 months ]
    record the serum concentration of TSH/T3/FT3/T4/FT4/TPOAb/TgAb/TRAb.

  5. Medical Cost [ Time Frame: up to 12 months ]
    record hospital expenditure

  6. Hospital Duration [ Time Frame: through study completion, an average of 7 days ]
    record hospital stay time

  7. Patient Satisfaction: questionnaire [ Time Frame: 5 years ]

    measured by satisfaction questionnaire designed by investigator group: items:

    1.Are you satisfied with surgery? 2.Are you satisfied with the RFA procedure? scale range from 1 to 10; by the increasing of scale, the outcome is defined as good.


  8. Anxiety index measured by psychological questionnaire [ Time Frame: up to 5 years ]
    1. I feel more nervous and anxious than usual (anxiety)
    2. I feel scared for no reason (fear)
    3. I am easily upset or frightened (frightened)
    4. I think I might be going crazy (madness) There are 20 questions (No. 5-20 don't show because of the 999 words restriction).

    scale range from 1 to 4 For the question 5,9,13,17,18, the outcome is define as good by the increasing of scale.

    For the others, the outcome is defined as bad by the increasting of scale.(scale 1=No or very few, scale2=sometimes, scale3=often, scale4=always)


  9. Overall Survival in Patients with PTMC [ Time Frame: 5 years ]
    record 5 year overall survival


Eligibility Criteria
Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Newly diagnosis of PTMC (largest dimension<10mm)
  • Age >=18 years old
  • Bethesda Category V or VI
  • Single nodule without thyroid capsule contact
  • Nodule has more than 3mm distance far from recurrent laryngeal nerve, carotid artery and trachea.
  • No clinical evidences show there is local or distant metastasis.
  • Without chemotherapy, radiotherapy and other related therapies.
  • Patients and their family member totally understand and sign the informed consent.

Exclusion Criteria:

  • Multifocal PTMC
  • Combined with other types of thyroid cancer or hyperthyroidism.
  • Contralateral vocal cord paralysis
  • With local or distant metastasis
  • Pregnant woman
  • With radiation exposure history
Contacts and Locations

Contacts
Layout table for location contacts
Contact: Pintong Huang, director +8618857168333 huangpintong@126.com
Contact: jifan Chen, collegue +8613605771565 chenjifan0619@163.com

Locations
Layout table for location information
China, Tianjin
General Surgery Department, Tianjin Medical University General Hospital Recruiting
Tianjin, Tianjin, China, 022
Contact: Jie Zhang, director    +8615822798742    wzq_bf@163.com   
Contact: Ruoyu Jiang, collegue    +8618622632394    jiangruoyu000@aliyun.com   
China, Zhejiang
Department of Ultrasound, Second Affiliated Hospital, School of Medicine, Zhejiang University Recruiting
Hangzhou, Zhejiang, China, 0571
Contact: Pintong Huang, director    +8618857168333    huangpintong@126.com   
Contact: Jifan Chen, collegue    +8613605771565    chenjifan0619@163.com   
Ukraine
Interventional Oncology Centre, State Institution "Grigoriev Intstitute for Medical Radiology NAMS of Ukraine" Not yet recruiting
Kharkiv, Ukraine, 61024
Contact: Sviatoslav Balaka    +380509356958    balaka.svjat@gmail.com   
Contact: Hennadii Hrechikhin    +380509188586    interv.oncology@gmail.com   
Sponsors and Collaborators
Second Affiliated Hospital, School of Medicine, Zhejiang University
Investigators
Layout table for investigator information
Principal Investigator: Pintong Huang, director Department of Ultrasound, Second Affiliated Hospital, School of Medicine, Zhejiang University
Tracking Information
First Submitted Date  ICMJE January 13, 2019
First Posted Date  ICMJE January 18, 2019
Last Update Posted Date December 19, 2020
Actual Study Start Date  ICMJE June 1, 2019
Estimated Primary Completion Date February 1, 2024   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: January 16, 2019)
Recurrent-free Survival Rate [ Time Frame: 5 years ]
record detecting recurrence of PTMC post-surgery or post-FRA
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: December 16, 2020)
  • The Diameter of Lesion [ Time Frame: 5 years ]
    record diameter reduce rate after RFA procedure
  • The Volume of Lesion [ Time Frame: 5 years ]
    record volume reduce rate after RFA procedure
  • Postoperative Complications [ Time Frame: up to 12 months ]
    record relevant complications after surgery or RFA
  • Serum Concentration of Serological Examination of Thyroid Function [ Time Frame: up to 12 months ]
    record the serum concentration of TSH/T3/FT3/T4/FT4/TPOAb/TgAb/TRAb.
  • Medical Cost [ Time Frame: up to 12 months ]
    record hospital expenditure
  • Hospital Duration [ Time Frame: through study completion, an average of 7 days ]
    record hospital stay time
  • Patient Satisfaction: questionnaire [ Time Frame: 5 years ]
    measured by satisfaction questionnaire designed by investigator group: items: 1.Are you satisfied with surgery? 2.Are you satisfied with the RFA procedure? scale range from 1 to 10; by the increasing of scale, the outcome is defined as good.
  • Anxiety index measured by psychological questionnaire [ Time Frame: up to 5 years ]
    1. I feel more nervous and anxious than usual (anxiety)
    2. I feel scared for no reason (fear)
    3. I am easily upset or frightened (frightened)
    4. I think I might be going crazy (madness) There are 20 questions (No. 5-20 don't show because of the 999 words restriction).
    scale range from 1 to 4 For the question 5,9,13,17,18, the outcome is define as good by the increasing of scale. For the others, the outcome is defined as bad by the increasting of scale.(scale 1=No or very few, scale2=sometimes, scale3=often, scale4=always)
  • Overall Survival in Patients with PTMC [ Time Frame: 5 years ]
    record 5 year overall survival
Original Secondary Outcome Measures  ICMJE
 (submitted: January 16, 2019)
  • The Diameter of Lesion [ Time Frame: 5 years ]
    record diameter reduce rate after RFA procedure
  • The Volume of Lesion [ Time Frame: 5 years ]
    record volume reduce rate after RFA procedure
  • Postoperative Complications [ Time Frame: up to 12 months ]
    record relevant complications after surgery or RFA
  • Serological Examination of Thyroid Function [ Time Frame: up to 12 months ]
    record items such as TSH/T3/FT3/T4/FT4/TPOAb/TgAb/TRAb
  • Medical Cost [ Time Frame: up to 12 months ]
    record hospital expenditure
  • Hospital Duration [ Time Frame: through study completion, an average of 7 days ]
    record hospital stay time
  • Patient Satisfaction: questionnaire [ Time Frame: 5 years ]
    measured by satisfaction questionnaire designed by investigator group: items: 1.Are you satisfied with surgery? 2.Are you satisfied with the RFA procedure? scale range from 1 to 10; by the increasing of scale, the outcome is defined as good.
  • Anxiety index measured by psychological questionnaire [ Time Frame: up to 5 years ]
    1. I feel more nervous and anxious than usual (anxiety)
    2. I feel scared for no reason (fear)
    3. I am easily upset or frightened (frightened)
    4. I think I might be going crazy (madness) There are 20 questions (No. 5-20 don't show because of the 999 words restriction).
    scale range from 1 to 4 For the question 5,9,13,17,18, the outcome is define as good by the increasing of scale. For the others, the outcome is defined as bad by the increasting of scale.(scale 1=No or very few, scale2=sometimes, scale3=often, scale4=always)
  • Overall Survival in Patients with PTMC [ Time Frame: 5 years ]
    record 5 year overall survival
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE A Multicenter Trial of Radiofrequency Ablation vs. Surgery as Treatment of Papillary Thyroid Microcarcinoma.
Official Title  ICMJE A Multicenter, Randomized and Controlled Trial of Radiofrequency Ablation vs. Conventional Surgery as Treatment of Papillary Thyroid Microcarcinoma (PTMC)
Brief Summary The treatment of Papillary Thyroid Microcarcinoma (PTMC) nowadays varies among physicians, surgeons and radiologist. The recently published articles show that the prognosis of PTMC by different means of treatment strategies tends to be good. But multicentered, randomized, parallel and prospective study is rare. RFA is the abbreviation of "Radiofrequency Ablation", which tends to be an alternative strategy except conventional surgery. The investigator aims to confirm whether RFA for treating PTMC braces same effectiveness and prognosis comparing with conventional surgery. Besides, this trial also investigates the safety, economy and psychological quality under different treatments.
Detailed Description

The incidence of thyroid carcinoma, especially the papillary thyroid microcarcinoma (PTMC), has increasingly rapidly, due to the development of technologies of diagnosis, during the past 20 years. PTMC defined by the World Health Organization (WTO) as the largest dimension less than 1 cm. Previous autopsy study demonstrated that the lesions are normal in many people and accompany them latently until they die because of another reasons. The long-term outcome of PTMC is good and, as expected, more than 90% PTMC aren't progress for many years.

Ultrasound-guided Radiofrequency Ablation (RFA) treatment was introduced to clinical practice few years ago. According to the 2015 American Thyroid Association (ATA) guideline, the treatment of radiofrequency and laser ablation are mentioned to be used in recurrent thyroid cancer. But clinical practice shows that the RFA treatment for low risk PTMC braces well effect,low financial budget,high safety and even rare postoperative complication.

Although the cohort study was performed before, the real answer concerning about whether RFA is a rational choice for treating PTMC lacks more powerful evidences. The investigator considers to perform a randomized, controlled and multicenter study as a high-quality evidence and demonstrated the effect of PRF in low risk PTMC treatment.

Study Type  ICMJE Interventional
Study Phase  ICMJE Not Applicable
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Papillary Thyroid Microcarcinoma
Intervention  ICMJE
  • Procedure: Radiofrequency Ablation
    Patients were supine with the neck exposure completely during the procedure. Local anesthesia with 1% lidocaine was injected at the subcutaneous puncture site and the thyroid anterior capsule. If the distance between the tumor and critical cervical structures was less than 5 mm, normal saline was injected to form at least 1 cm distance between the tumor and the critical structure to prevent the unwilling thermal injury. RFA was performed using the moving-shot technique and RFA power was 5 W, if a transient hyperechoic zone did not form at the electrode tip within 5-10 seconds. The RFA extent exceeded the tumor edge to prevent marginal residue and recurrence. The ablation was terminated when all portions of the target ablation area had changed to hyperechoic zones.
    Other Name: RFA
  • Procedure: Conventional Surgery
    Patient is performed total thyroidectomy or thyroid lobectomy depending on the intraoperative situation, disease condition and comprehensive judge by surgeon. Patients are routinely disinfected and spread the drapes after general anesthesia. Neck skin, fat and placenta muscle are incised and separated successively. The flap is separated to the upper edge of thyroid cartilage, neck white line is incised and anterior muscle group is separated. Then both sides thyroid lobes are exposed. Cut off the isthmus, ligature the thyroid artery, cut off the upper pole. Ligature and cut off the ipsilateral thyroid vein. Reveal and protect the ipsilateral recurrent laryngeal nerve and the parathyroid gland during the entire process.
    Other Name: Total thyroidectomy/Thyroid lobectomy
Study Arms  ICMJE
  • Experimental: Radiofrequency Ablation
    Eligible participants with PTMC will be randomly assigned to this group and undergo radiofrequency ablation(RFA) procedure.
    Intervention: Procedure: Radiofrequency Ablation
  • Active Comparator: Conventional Surgery
    Eligible participants with PTMC will be randomly assigned to this group and undergo total/thyroid lobectomy procedure.
    Intervention: Procedure: Conventional Surgery
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: January 16, 2019)
200
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE February 1, 2024
Estimated Primary Completion Date February 1, 2024   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Newly diagnosis of PTMC (largest dimension<10mm)
  • Age >=18 years old
  • Bethesda Category V or VI
  • Single nodule without thyroid capsule contact
  • Nodule has more than 3mm distance far from recurrent laryngeal nerve, carotid artery and trachea.
  • No clinical evidences show there is local or distant metastasis.
  • Without chemotherapy, radiotherapy and other related therapies.
  • Patients and their family member totally understand and sign the informed consent.

Exclusion Criteria:

  • Multifocal PTMC
  • Combined with other types of thyroid cancer or hyperthyroidism.
  • Contralateral vocal cord paralysis
  • With local or distant metastasis
  • Pregnant woman
  • With radiation exposure history
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Pintong Huang, director +8618857168333 huangpintong@126.com
Contact: jifan Chen, collegue +8613605771565 chenjifan0619@163.com
Listed Location Countries  ICMJE China,   Ukraine
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03808779
Other Study ID Numbers  ICMJE 2013-004-A012
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: Undecided
Responsible Party huang pintong, Second Affiliated Hospital, School of Medicine, Zhejiang University
Study Sponsor  ICMJE Second Affiliated Hospital, School of Medicine, Zhejiang University
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Principal Investigator: Pintong Huang, director Department of Ultrasound, Second Affiliated Hospital, School of Medicine, Zhejiang University
PRS Account Second Affiliated Hospital, School of Medicine, Zhejiang University
Verification Date December 2020

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP